Stockchase Opinions

Werner Muehelemann Zoomd ZOMD-X COMMENT May 28, 2008

Communication device going from doctor to pharmacy. Have had good success. Good customer base. Still at the early stages. A micro cap and still needs to be well financed in order to expand its technology to be used in every hospital in North America. Good track record to now.
$0.390

Stock price when the opinion was issued

electrical electronic
It's the ideal tool to help you make quicker, more informed decisions for managing and tracking your investments.

You might be interested:

WEAK BUY
Communication device for doctors relaying prescriptions to the pharmacy. Not in his database. Big installed base in Quebec and rolling into Ontario. Very speculative.
BUY
Has raised capital. Produces a hand held company to assist primary care physicians, to help electronic prescribing. It doesn’t cost the physician anything. The company is doing very well.
BUY
Emerging development stage. Doesn’t have a ton of cash. May be able to get some cash from the government.
COMMENT
Communication device between doctor and pharmacist. Great product. Federal government is encouraging electronic equipment like this and he is expecting it to come to some kind of agreement over the next 3 months but need money in the meantime.
HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

Sales rose 40% to $19.6M. EBITDA rose 80% to $5.6M. Net income was $6.1M vs $3.9M last year. Cash flow was $5.2M, with cash at $16.5M. North America and Europe were highlight areas. Costs rose slower than sales so margins improved. We would consider these results very good and with the gain in market cap and valuation we can see why the stock is doing very well this year.
Unlock Premium - Try 5i Free    

HOLD
Trevor Rose’s Insights - Trevor’s most-liked answers from 5i Research

Sales rose 40% to $19.6M. EBITDA rose 80% to $5.6M. Net income was $6.1M vs $3.9M last year. Cash flow was $5.2M, with cash at $16.5M. North America and Europe were highlight areas. Costs rose slower than sales so margins improved. We would consider these results very good and with the gain in market cap and valuation we can see why the stock is doing very well this year.
Unlock Premium - Try 5i Free